Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
暂无分享,去创建一个
[1] S H Ferris,et al. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. , 1996, JAMA.
[2] K Herholz,et al. FDG PET and Differential Diagnosis of Dementia , 1995, Alzheimer disease and associated disorders.
[3] A. Alavi,et al. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. , 1982, The American journal of psychiatry.
[4] B. Gordon,et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.
[5] M. Wittekind,et al. Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. , 2003, Archives of biochemistry and biophysics.
[6] M. Spieth,et al. A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] Dementia: Causes, Evaluation, and Management , 2001, Hospital practice.
[8] J. Price,et al. Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.
[9] B. Miller,et al. CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[10] J. Haxby. Resting state regional cerebral metabolism in dementia of the Alzheimer type , 1990 .
[11] A. Convit,et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.
[12] D. Benson,et al. Positron emission computed tomography in the diagnosis of dementia. , 1981, Transactions of the American Neurological Association.
[13] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[14] M H Buonocore,et al. Brain structure and cognition in a community sample of elderly Latinos , 2002, Neurology.
[15] H. Chui,et al. Multicenter clinicopathological correlation in dementia. , 1995, The American journal of psychiatry.
[16] P. Tariot,et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.
[17] R. Hoffman. Diagnostic errors in the evaluation of behavioral disorders. , 1982, JAMA.
[18] William J Jagust,et al. Brain function and cognition in a community sample of elderly Latinos , 2002, Neurology.
[19] S H Ferris,et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. , 1997, JAMA.
[20] G. Waldemar,et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[21] K. Jobst,et al. Accurate Prediction of Histologically Confirmed Alzheimer's Disease and the Differential Diagnosis of Dementia: The Use of NINCDS-ADRDA and DSM-III-R Criteria, SPECT, X-Ray CT, and Apo E4 in Medial Temporal Lobe Dementias , 1997, International Psychogeriatrics.
[22] O Almkvist,et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment , 2001, Neuroreport.
[23] B. Reisberg,et al. Positron emission tomography in dementia. , 1983, Advances in neurology.
[24] S S Gambhir,et al. A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] M. Bobinski,et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Coyle,et al. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease , 2001, Biological Psychiatry.
[27] Richard S. J. Frackowiak,et al. The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.
[28] K. Någren,et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[29] B J Shepstone,et al. Accurate Prediction of Histologically Confirmed Alzheimer's Disease and the Differential Diagnosis of Dementia: The Use of NINCDS-ADRDA and DSM-III-R Criteria, SPECT, X-Ray CT, and Apo E4 in Medial Temporal Lobe Dementias , 1998, International Psychogeriatrics.
[30] Karl J. Friston,et al. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions , 1993, Psychological Medicine.
[31] N. Foster,et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.
[32] Michael D. Devous,et al. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[33] F Zito,et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Klemens Scheidhauer,et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] W M Tierney,et al. Documentation and Evaluation of Cognitive Impairment in Elderly Primary Care Patients , 1995, Annals of Internal Medicine.
[36] G. Alexander,et al. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[37] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[38] L. Wilkins. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.
[39] Michael E. Phelps,et al. Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[40] R. Coleman,et al. Interpretation variability of 18FDG-positron emission tomography studies in dementia. , 1996, Investigative radiology.
[41] Functional Cerebral SPECT and PET Imaging , 2000 .
[42] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[43] R B D'Agostino,et al. Incidence of dementia and probable Alzheimer's disease in a general population , 1993, Neurology.
[44] G. Small,et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. , 2003, Molecular Genetics and Metabolism.
[45] T Jones,et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. , 1981, Brain : a journal of neurology.
[46] J. Hoffman,et al. FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] Positron and single photon emission tomography in the differential diagnosis of dementia , 1990 .
[48] Peter J. Ell,et al. Nuclear medicine in clinical diagnosis and treatment , 2004 .
[49] A. Drzezga,et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[50] K. Ishii,et al. Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] G. Alexander,et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.
[52] Gereon R. Fink,et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern , 1994, European Journal of Nuclear Medicine.